Table 4.
Number of patients with antibiotics de-escalation (change from empirical to targeted antibiotics) in the pre-BCID2 and BCID2 study groups.
| Study Population | Patients According to Antibiotics Change, N (%) | ||
|---|---|---|---|
| No Record of Antibiotics Change 1 |
Change to Targeted Antibiotics 2 | Unknown 3 | |
| Pre-BCID2 phase (n = 99) | 4 (4.0%) | 94 (94.9%) | 1 (1.0%) |
| BCID2 phase (n = 86) | 3 (3.5%) | 82 (95.3%) | 1 (1.2%) |
1 Patients with a record of ordered empirical antibiotics only; 2 Patients with a record of ordered empirical antibiotics and of antibiotics change to optimal therapy following test result (pathogen identification or susceptibility result); 3 Antibiotics change could not be determined due to a missing record on empirical and/or targeted therapy.